Quantitative Concept
Medicare Patients to Save on 64 Prescription Drugs with Prices Above Inflation Rate
Medicare, Prescription Drugs, Inflation Reduction Act, Price Rebates, Healthcare Costs
Curie.Bio Raises $380M to Support Early-Stage Biotechs
Curie.Bio, biotech accelerator, venture capital, Series A rounds, early-stage biotechs, Alexis Borisy, Zach Weinberg
AstraZeneca’s Imfinzi Achieves Success in Bladder Cancer Trial, Falls Short in Lung Cancer Study
AstraZeneca, Imfinzi, bladder cancer, lung cancer, Phase III trials, disease-free survival
PTC Therapeutics Reports Positive Phase II Huntington’s Disease Data, FDA Lifts Partial Clinical Hold
PTC Therapeutics, Huntington’s disease, Phase II data, FDA, partial clinical hold, PTC518, mutant huntingtin protein, clinical trends, safety, tolerability.
Johnson & Johnson Invests €580 Million in Italian Manufacturing Operations Over Five Years
Johnson & Johnson, Italy, Manufacturing, Investment, Capacity Upgrade, Research and Development, Pharmaceutical Industry
FDA Places Partial Clinical Hold on Zentalis’ Azenosertib Cancer Studies Following Two Sepsis Deaths
Zentalis Pharmaceuticals, azenosertib, FDA, partial clinical hold, cancer studies, sepsis deaths, WEE1 inhibitor, clinical trials, patient safety
FTC Supports Rule Change to Expose Anticompetitive Drug Patent Deals
FTC, antitrust, drug patent deals, pharmaceutical companies, patent settlements, competition, generic drugs, price regulation
AstraZeneca’s Truqap Combo Fails to Improve Survival in Phase III Triple-Negative Breast Cancer Trial
AstraZeneca, Truqap, capivasertib, Phase III trial, triple-negative breast cancer, CAPItello-290, paclitaxel, overall survival, PIK3CA, AKT1, PTEN
Decheng Capital Seeks $700 Million for Fifth Life Sciences Fund Amidst VC Surge
Decheng Capital, Life Sciences Fund, Venture Capital, Biotechnology, Investment Firm
Gilead’s Magrolimab Linked to Increased Risk of Death in Blood Cancer Patients
Gilead, Magrolimab, Blood Cancer, Increased Risk of Death, ENHANCE Study